Skip to main content
OpenTrials

Clinical trial condition

Peripheral T Cell Lymphoma

Explore clinical trials studying Peripheral T Cell Lymphoma. Study availability and eligibility vary by location and protocol.

52 public trials 24 recruiting studies
Refine in advanced search Browse all conditions

Peripheral T Cell Lymphoma trial results

Completed

Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma

NCT03927105

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan, United States
  • Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
  • Unviersity of Wisconsin Madison, Wisconsin, United States
View Trial Details
Completed

AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27)

NCT06511895

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • Anhui Provincial Hospital (The First Affiliated Hospital of USTC) Hefei, Anhui, China
  • The Second Hospital of Anhui Meidcine University Hefei, Anhui, China
  • Beijing Cancer Hospital Beijing, Beijing Municipality, China
  • Peking University Third Hospital Beijing, Beijing Municipality, China
View all 19 locations
View Trial Details
Completed

BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I)

NCT04018248

Conditions
B Cell Lymphoma, Blood Protein Disorders, Cardiovascular Diseases, +36 more
Locations
  • Henry Ford Hospital Detroit, Michigan, United States
  • National Cancer Center Goyang-si, Gyeonggi-do, South Korea
  • Seoul National University Bundang Hospital Seongnam-si, Gyeonggi-do, South Korea
  • Chonnam National University Hwasun Hospital Hwasun, Jeollanam-do, South Korea
View Trial Details
Completed

Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides

NCT04101331

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +10 more
Locations
  • University of Alabama at Birmingham (O'Neal Comprehensive Cancer Center) Birmingham, Alabama, United States
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • University of California Los Angeles (UCLA) Health Los Angeles, California, United States
  • Emory University Clinic/Winship Cancer Institute Atlanta, Georgia, United States
View all 69 locations
View Trial Details
Completed

Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms

NCT03493451

Conditions
ALK-Positive Anaplastic Large Cell Lymphoma, ALK-negative Anaplastic Large Cell Lymphoma, Adult Nasal Type Extranodal NK/T-cell Lymphoma, +36 more
Locations
  • British Columbia Cancer Agency the Vancouver Centre Vancouver, British Columbia, Canada
  • Peking University Third Hospital Beijing, Beijing Municipality, China
  • Beijing Hospital Beijing, Beijing Municipality, China
  • Peking Union Medical College Hospital Beijing, Beijing Municipality, China
View all 24 locations
View Trial Details
Completed

A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)

NCT01716806

Conditions
Hematologic Diseases, Hemic and Lymphatic Diseases, Hodgkin Disease, +11 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • University of South Alabama - Mitchell Cancer Institute Mobile, Alabama, United States
  • Alaska Urological Institute Anchorage, Alaska, United States
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
View all 54 locations
View Trial Details

Related conditions